TY - JOUR ID - 12644 TI - Curcumin effects on myeloperoxidase, interleukin-18 and matrix metalloproteinase-9 inflammatory biomarkers in patients with unstable angina: A randomized clinical trial JO - Avicenna Journal of Phytomedicine JA - AJP LA - en SN - 2228-7930 AU - Mohammad pour, Amir hooshang AU - Dastani, Mostafa AU - Salari, Roshanak AU - Radbin, Sohrab AU - Mehri, Soghra AU - Ghorbani, Maryam AU - Karimani, Asieh AU - Salari, Masoumeh AD - Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. AD - Department of Cardiology, Ghaem Hospital, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. AD - Department of Clinical Persian Pharmacy, School of Persian and Complementary Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. AD - Pharmaceutical Research Center, Institute of Pharmaceutical Technology, Mashhad University of Medical Sciences, Mashhad, Iran. AD - Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran AD - Department of Pharmacology and Toxicology, School of Pharmacy, Baqiyatallah University of Medical Sciences, Tehran, Iran. AD - Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. AD - Department of Internal Medicine, Ghaem Hospital, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Y1 - 2019 PY - 2019 VL - 9 IS - 5 SP - 428 EP - 435 KW - Curcumin KW - Interlukein-18 KW - Myeloperoxidase KW - Matrix metalloproteinase-9 KW - Unstable angina DO - 10.22038/ajp.2019.12644 N2 - Objective: Inflammation along with oxidative stress plays an important role in the development, progression, instability and rupture of coronary atherosclerotic plaques. Several studies introduced curcumin (diferuloylmethane) as a wonderful chemical in Curcuma longa (turmeric) with appropriate anti-inflammatory and antioxidant effects. The effect of curcumin on inflammatory biomarkers was assessed in several clinical trials. This study was designed to evaluate the effect of curcumin on three pro-inflammatory biomarkers in patients with unstable angina. Materials and Methods: Forty patients with unstable angina who met the inclusion criteria, participated in this double-blind randomized clinical trial. Patients were randomly divided into two groups. The patients in the treatment group received nanocurcumin 80 mg per day for 5 days and the control group received placebo 80 mg per day for five days. Blood samples were obtained before the administration, and also 1, 2 and 4 days after taking the treatment. Serum concentrations of Myeloperoxidase (MPO), matrix metalloproteinase-9 (MMP-9) and interleukin 18 (IL-18) biomarkers were measured by ELISA. Results: There was no significant difference in concentration of these biomarkers before the administration and 1, 2 and 4 days after the start of the trial, between the two groups; however, the concentration of IL-18 on the first day significantly varied between the groups. Conclusion: Based on the findings of this study, administration of nanocurcumin capsules at the dose of 80 mg per day for 5 days, did not significantly decrease inflammatory biomarkers in patients with unstable angina. UR - https://ajp.mums.ac.ir/article_12644.html L1 - https://ajp.mums.ac.ir/article_12644_fee71c2082c660af6ee96286e33aac36.pdf ER -